UTHR Q1 2019 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$363M-6.8% YoY

Gross Profit

$334M92.0% margin

Operating Income

-$656M-180.9% margin

Net Income

-$495M-136.4% margin

EPS (Diluted)

$-11.32

QoQ Revenue Growth

-4.9%

Cash Flow

Operating Cash Flow

-$627M

Free Cash Flow

-$653M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$1.4B

Stockholders' Equity

$2.3B

Cash & Equivalents

$791M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$363M	$389M	-6.8%
Gross Profit	$334M	$336M	-0.7%
Operating Income	-$656M	$307M	-313.7%
Net Income	-$495M	$245M	-302.3%

Revenue Segments

Remodulin

$156M43%

Tyvaso

$104M29%

Adcirca

$58M16%

Orenitram

$25M7%

Unituxin

$20M6%

Geographic Segments

U

$330M91%

European Union And Others

$33M9%